<?xml version='1.0' encoding='utf-8'?>
<document id="22095822"><sentence text="Mrp2 is involved in the efflux and disposition of fosinopril."><entity charOffset="50-60" id="DDI-PubMed.22095822.s1.e0" text="fosinopril" /></sentence><sentence text="The multidrug-resistance-associated proteins 1 and 2 (MRP1/MRP2) are transporters responsible for the efflux of drugs and endogenous compounds" /><sentence text=" Madin Darby canine kidney (MDCK) cells transfected with the human MRP1 or MRP2 genes were used to assess whether several widely used pharmaceuticals are potential substrates by examining their differential toxicity, accumulation and efflux" /><sentence text=" Loratadine, an antihistamine, was 1"><entity charOffset="1-11" id="DDI-PubMed.22095822.s4.e0" text="Loratadine" /></sentence><sentence text="4-fold less toxic to MRP1 cells and its retention was 1" /><sentence text="3-fold lower than that from MDCK control cells" /><sentence text=" Fosinopril, an angiotensin converting enzyme inhibitor, was 2"><entity charOffset="1-11" id="DDI-PubMed.22095822.s7.e0" text="Fosinopril" /><entity charOffset="16-27" id="DDI-PubMed.22095822.s7.e1" text="angiotensin" /><pair ddi="false" e1="DDI-PubMed.22095822.s7.e0" e2="DDI-PubMed.22095822.s7.e0" /><pair ddi="false" e1="DDI-PubMed.22095822.s7.e0" e2="DDI-PubMed.22095822.s7.e1" /></sentence><sentence text="4-fold less toxic and its retention was 4" /><sentence text="5-fold lower in MRP2-transfected cells compared with control cells" /><sentence text=" To determine whether fosinopril contributed to a drug-drug interaction, fosinopril efflux was examined in vitro in combination with other known or suspected MRP2 substrates over a period of 20 min"><entity charOffset="22-32" id="DDI-PubMed.22095822.s10.e0" text="fosinopril" /><entity charOffset="73-83" id="DDI-PubMed.22095822.s10.e1" text="fosinopril" /><pair ddi="false" e1="DDI-PubMed.22095822.s10.e0" e2="DDI-PubMed.22095822.s10.e0" /><pair ddi="false" e1="DDI-PubMed.22095822.s10.e0" e2="DDI-PubMed.22095822.s10.e1" /></sentence><sentence text=" When fosinopril was coincubated with desloratadine, loratadine or methotrexate, its retention was increased by 2-, 4"><entity charOffset="6-16" id="DDI-PubMed.22095822.s11.e0" text="fosinopril" /><entity charOffset="38-51" id="DDI-PubMed.22095822.s11.e1" text="desloratadine" /><entity charOffset="53-63" id="DDI-PubMed.22095822.s11.e2" text="loratadine" /><entity charOffset="67-79" id="DDI-PubMed.22095822.s11.e3" text="methotrexate" /><pair ddi="false" e1="DDI-PubMed.22095822.s11.e0" e2="DDI-PubMed.22095822.s11.e0" /><pair ddi="false" e1="DDI-PubMed.22095822.s11.e0" e2="DDI-PubMed.22095822.s11.e1" /><pair ddi="false" e1="DDI-PubMed.22095822.s11.e0" e2="DDI-PubMed.22095822.s11.e2" /><pair ddi="false" e1="DDI-PubMed.22095822.s11.e0" e2="DDI-PubMed.22095822.s11.e3" /><pair ddi="false" e1="DDI-PubMed.22095822.s11.e1" e2="DDI-PubMed.22095822.s11.e1" /><pair ddi="false" e1="DDI-PubMed.22095822.s11.e1" e2="DDI-PubMed.22095822.s11.e2" /><pair ddi="false" e1="DDI-PubMed.22095822.s11.e1" e2="DDI-PubMed.22095822.s11.e3" /><pair ddi="false" e1="DDI-PubMed.22095822.s11.e2" e2="DDI-PubMed.22095822.s11.e2" /><pair ddi="false" e1="DDI-PubMed.22095822.s11.e2" e2="DDI-PubMed.22095822.s11.e3" /></sentence><sentence text="7- and 2-fold, respectively, which likely indicates that a drug-drug interaction is occurring" /><sentence text=" In vivo studies were conducted, in which FVB wild-type and FVB/Mrp2(-/-) mice were dosed with fosinopril and the known MRP2 substrate methotrexate, and tissues collected after 1 h"><entity charOffset="95-105" id="DDI-PubMed.22095822.s13.e0" text="fosinopril" /><entity charOffset="135-147" id="DDI-PubMed.22095822.s13.e1" text="methotrexate" /><pair ddi="false" e1="DDI-PubMed.22095822.s13.e0" e2="DDI-PubMed.22095822.s13.e0" /><pair ddi="false" e1="DDI-PubMed.22095822.s13.e0" e2="DDI-PubMed.22095822.s13.e1" /></sentence><sentence text=" In mice lacking Mrp2, drug levels were reduced in the intestine by 1" /><sentence text="5-fold, but increased in the liver, serum and kidneys, by 2" /><sentence text="1-, 2" /><sentence text="9- and 3-fold, respectively" /><sentence text=" These data suggest that, in the absence of Mrp2, fosinopril alters the retention of a second drug"><entity charOffset="50-60" id="DDI-PubMed.22095822.s18.e0" text="fosinopril" /></sentence><sentence text=" These findings will help increase our understanding of the role that MRP2 plays in altering the retention and disposition of coadministered pharmaceuticals" /><sentence text="" /></document>